156 related articles for article (PubMed ID: 19090779)
1. Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching.
Wei D; Jiang X; Zhou L; Chen J; Chen Z; He C; Yang K; Liu Y; Pei J; Lai L
J Med Chem; 2008 Dec; 51(24):7882-8. PubMed ID: 19090779
[TBL] [Abstract][Full Text] [Related]
2. Hybrid Receptor-Bound/MM-GBSA-Per-residue Energy-Based Pharmacophore Modelling: Enhanced Approach for Identification of Selective LTA4H Inhibitors as Potential Anti-inflammatory Drugs.
Appiah-Kubi P; Soliman M
Cell Biochem Biophys; 2017 Mar; 75(1):35-48. PubMed ID: 27914004
[TBL] [Abstract][Full Text] [Related]
3. Optimization of 5-hydroxytryptamines as dual function inhibitors targeting phospholipase A2 and leukotriene A4 hydrolase.
Meng H; Liu Y; Zhai Y; Lai L
Eur J Med Chem; 2013 Jan; 59():160-7. PubMed ID: 23220644
[TBL] [Abstract][Full Text] [Related]
4. Discovery of dual target inhibitors against cyclooxygenases and leukotriene A4 hydrolyase.
Chen Z; Wu Y; Liu Y; Yang S; Chen Y; Lai L
J Med Chem; 2011 May; 54(10):3650-60. PubMed ID: 21542630
[TBL] [Abstract][Full Text] [Related]
5. Identification of Human Leukotriene A4 Hydrolase Inhibitors Using Structure-Based Pharmacophore Modeling and Molecular Docking.
Audat SA; Al-Shar'i NA; Al-Oudat BA; Bryant-Friedrich A; Bedi MF; Zayed AL; Al-Balas QA
Molecules; 2020 Jun; 25(12):. PubMed ID: 32580506
[TBL] [Abstract][Full Text] [Related]
6. Molecular docking and pharmacophore filtering in the discovery of dual-inhibitors for human leukotriene A4 hydrolase and leukotriene C4 synthase.
Thangapandian S; John S; Sakkiah S; Lee KW
J Chem Inf Model; 2011 Jan; 51(1):33-44. PubMed ID: 21133343
[TBL] [Abstract][Full Text] [Related]
7. High-affinity aptamers selectively inhibit human nonpancreatic secretory phospholipase A2 (hnps-PLA2).
Bridonneau P; Chang YF; O'Connell D; Gill SC; Snyder DW; Johnson L; Goodson T; Herron DK; Parma DH
J Med Chem; 1998 Mar; 41(6):778-86. PubMed ID: 9526554
[TBL] [Abstract][Full Text] [Related]
8. Activation and inhibition of leukotriene A4 hydrolase aminopeptidase activity by diphenyl ether and derivatives.
Jiang X; Zhou L; Wei D; Meng H; Liu Y; Lai L
Bioorg Med Chem Lett; 2008 Dec; 18(24):6549-52. PubMed ID: 18952425
[TBL] [Abstract][Full Text] [Related]
9. Dual anti-inflammatory and selective inhibition mechanism of leukotriene A4 hydrolase/aminopeptidase: insights from comparative molecular dynamics and binding free energy analyses.
Appiah-Kubi P; Soliman ME
J Biomol Struct Dyn; 2016 Nov; 34(11):2418-33. PubMed ID: 26555301
[TBL] [Abstract][Full Text] [Related]
10. Diverse ways of perturbing the human arachidonic acid metabolic network to control inflammation.
Meng H; Liu Y; Lai L
Acc Chem Res; 2015 Aug; 48(8):2242-50. PubMed ID: 26237215
[TBL] [Abstract][Full Text] [Related]
11. Discovery of potent inhibitors of soluble epoxide hydrolase by combinatorial library design and structure-based virtual screening.
Xing L; McDonald JJ; Kolodziej SA; Kurumbail RG; Williams JM; Warren CJ; O'Neal JM; Skepner JE; Roberds SL
J Med Chem; 2011 Mar; 54(5):1211-22. PubMed ID: 21302953
[TBL] [Abstract][Full Text] [Related]
12. Unsymmetrical non-adamantyl N,N'-diaryl urea and amide inhibitors of soluble expoxide hydrolase.
Anandan SK; Webb HK; Do ZN; Gless RD
Bioorg Med Chem Lett; 2009 Aug; 19(15):4259-63. PubMed ID: 19520575
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel and potent aryl diamines as leukotriene A4 hydrolase inhibitors.
Khim SK; Bauman J; Evans J; Freeman B; King B; Kirkland T; Kochanny M; Lentz D; Liang A; Mendoza L; Phillips G; Tseng JL; Wei RG; Ye H; Yu L; Parkinson J; Guilford WJ
Bioorg Med Chem Lett; 2008 Jul; 18(14):3895-8. PubMed ID: 18590959
[TBL] [Abstract][Full Text] [Related]
14. Discovery of DPP IV inhibitors by pharmacophore modeling and QSAR analysis followed by in silico screening.
Al-Masri IM; Mohammad MK; Taha MO
ChemMedChem; 2008 Nov; 3(11):1763-79. PubMed ID: 18989859
[TBL] [Abstract][Full Text] [Related]
15. Molecular dynamics simulation study and hybrid pharmacophore model development in human LTA4H inhibitor design.
Thangapandian S; John S; Arooj M; Lee KW
PLoS One; 2012; 7(4):e34593. PubMed ID: 22496831
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Potent Soluble Epoxide Hydrolase (sEH) Inhibitors by Pharmacophore-Based Virtual Screening.
Waltenberger B; Garscha U; Temml V; Liers J; Werz O; Schuster D; Stuppner H
J Chem Inf Model; 2016 Apr; 56(4):747-62. PubMed ID: 26882208
[TBL] [Abstract][Full Text] [Related]
17. Identification by virtual screening and in vitro testing of human DOPA decarboxylase inhibitors.
Daidone F; Montioli R; Paiardini A; Cellini B; Macchiarulo A; Giardina G; Bossa F; Borri Voltattorni C
PLoS One; 2012; 7(2):e31610. PubMed ID: 22384042
[TBL] [Abstract][Full Text] [Related]
18. Development and evaluation of a pharmacophore model for inhibitors of aldosterone synthase (CYP11B2).
Ulmschneider S; Negri M; Voets M; Hartmann RW
Bioorg Med Chem Lett; 2006 Jan; 16(1):25-30. PubMed ID: 16246562
[TBL] [Abstract][Full Text] [Related]
19. PENG: a neural gas-based approach for pharmacophore elucidation. method design, validation, and virtual screening for novel ligands of LTA4H.
Moser D; Wittmann SK; Kramer J; Blöcher R; Achenbach J; Pogoryelov D; Proschak E
J Chem Inf Model; 2015 Feb; 55(2):284-93. PubMed ID: 25625859
[TBL] [Abstract][Full Text] [Related]
20. Pharmacophore identification, in silico screening, and virtual library design for inhibitors of the human factor Xa.
Krovat EM; Frühwirth KH; Langer T
J Chem Inf Model; 2005; 45(1):146-59. PubMed ID: 15667140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
